한글목차

APP13007(클로베타졸 프로피온산 에스테르 점안용 나노현탁액)은 코르티코스테로이드인 클로베타졸 프로피온산 에스테르를 나노밀링하여 부형제의 혼합물과 함께 다제 보존 수성 제제에 분산시킨 점안용 나노현탁액입니다. 독자적인 나노 밀링 기술은 프로피온산 클로베타졸을 수성 현탁액으로 제형화할 수 있습니다. APP13007에서 프로피온산 클로베타졸 나노입자의 이러한 현탁액은 눈 표면에 점안할 때 프로피온산 클로베타졸의 눈 내로의 효율적인 침투를 가능하게 하고, 치료적으로 적절한 농도의 프로피오네이트 클로베타졸을 눈 내의 표적 조직에 전달하도록 설계되었습니다. APP13007은 안과 수술 후 염증 및 통증 치료제로 개발되었습니다.

Activus는 당초 특허를 취득한 독자적인 APNT(Activus Pure Nanoparticle Technology)를 부신피질스테로이드인 프로피온산 클로베타졸에 적용하여 눈의 수술후 염증을 치료하기 위한 신규 나노입자 제제를 창조함으로써 APP13007 를 개발했습니다. Activus는 2017년 8월에 Formosa에 판매되었습니다. 판매 후 Formosa는 APP13007의 개발을 진행하고 있습니다.

앞으로 몇 년동안 세계의 광범위한 조사와 의료 지출 증가로 수술 후 통증 시장 시나리오가 바뀝니다. 각 회사는 병태를 치료/개선하기 위한 새로운 접근법에 중점을 둔 치료법을 개발하고, 과제를 평가하고, APP13007의 이점에 영향을 줄 수 있는 기회를 모색하고 있습니다. 수술 후 통증에 대한 다른 신흥 제품은 APP13007에 엄격한 시장 경쟁을 가져올 것으로 예상되며, 가까운 미래에 후발 신흥 치료제가 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.

본 보고서는 주요 7개국에서 APP13007 시장을 조사했으며, 시장 개요와 함께 경쟁 구도, 2032년까지 시장 규모 예측, 국가별 시장 분석 등을 제공합니다.

목차

제1장 보고서 소개

제2장 수술 후 통증에 있어서의 APP13007의 개요

• 제품 상세
• 임상 개발
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료법

제4장 경쟁 구도(후기 단계의 신흥 치료법

제5장 APP13007 시장 평가

• 수술 후 통증에서 APP13007 시장 전망
• 주요 7개국 분석
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 정보

제12장 보고서 구매 옵션

영문목차

"APP13007 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about APP13007 for Postoperative pain in the seven major markets. A detailed picture of the APP13007 for Postoperative pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the APP13007 for Postoperative pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the APP13007 market forecast analysis for Postoperative pain in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Postoperative pain.

Drug Summary:

APP13007 (clobetasol propionate ophthalmic nanosuspension) is an ophthalmic nanosuspension prepared by dispersing nanomilled clobetasol propionate, a corticosteroid, with a mixture of excipients in a multi-dose preserved aqueous formulation. The proprietary nanomilling technology allows clobetasol propionate to be formulated as an aqueous suspension. This suspension of clobetasol propionate nanoparticles in APP13007 is designed to enable efficient penetration of clobetasol propionate into the eye upon ocular surface instillation and deliver therapeutically relevant concentrations of clobetasol propionate to the target tissues within the eye. APP13007 is being developed for the treatment of postoperative inflammation and pain following ocular surgery.

Activus originally developed APP13007 by applying its patented proprietary APNT (Activus Pure Nanoparticle Technology) to the corticosteroid clobetasol propionate to create a novel nanoparticle formulation for treating postoperative inflammation of the eye. Activus was divested in August 2017 to Formosa. Since the divestment, Formosa has progressed in the development of APP13007.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the APP13007 description, mechanism of action, dosage and administration, research and development activities in Postoperative pain.
• Elaborated details on APP13007 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the APP13007 research and development activities in Postoperative pain across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around APP13007.
• The report contains forecasted sales of APP13007 for Postoperative pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Postoperative pain.
• The report also features the SWOT analysis with analyst views for APP13007 in Postoperative pain.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

APP13007 Analytical Perspective by DelveInsight

• In-depth APP13007 Market Assessment

This report provides a detailed market assessment of APP13007 for Postoperative pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• APP13007 Clinical Assessment

The report provides the clinical trials information of APP13007 for Postoperative pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Postoperative pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence APP13007 dominance.
• Other emerging products for Postoperative pain are expected to give tough market competition to APP13007 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of APP13007 in Postoperative pain.
• Our in-depth analysis of the forecasted sales data of APP13007 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the APP13007 in Postoperative pain.

Key Questions:

• What is the product type, route of administration and mechanism of action of APP13007?
• What is the clinical trial status of the study related to APP13007 in Postoperative pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the APP13007 development?
• What are the key designations that have been granted to APP13007 for Postoperative pain?
• What is the forecasted market scenario of APP13007 for Postoperative pain?
• What are the forecasted sales of APP13007 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to APP13007 for Postoperative pain?
• Which are the late-stage emerging therapies under development for the treatment of Postoperative pain?

Table of Contents

1. Report Introduction

2. APP13007 Overview in Postoperative pain

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. APP13007 Market Assessment

• 5.1. Market Outlook of APP13007 in Postoperative pain
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of APP13007 in the 7MM for Postoperative pain
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of APP13007 in the United States for Postoperative pain
  • 5.3.2. Market Size of APP13007 in Germany for Postoperative pain
  • 5.3.3. Market Size of APP13007 in France for Postoperative pain
  • 5.3.4. Market Size of APP13007 in Italy for Postoperative pain
  • 5.3.5. Market Size of APP13007 in Spain for Postoperative pain
  • 5.3.6. Market Size of APP13007 in the United Kingdom for Postoperative pain
  • 5.3.7. Market Size of APP13007 in Japan for Postoperative pain

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options